Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion type Assertion NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_head.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion description "[Next, the histological differences were recognized that the patients with RUNX3 methylation had a shorter duration of survival in adenocarcinomas (ACs) (P=0.045), in contrast to those with RASSF1A methylation who had a shorter duration of survival in squamous cell carcinomas (SCCs) (P=0.021).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_provenance.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion evidence source_evidence_literature NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_provenance.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion SIO_000772 17606310 NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_provenance.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion wasDerivedFrom befree-20140225 NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_provenance.
- NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_assertion wasGeneratedBy ECO_0000203 NP318199.RA6nACXSPynVGblNc7eF5tAn3HKXmcMG6yEPoY0hY5SWY130_provenance.